Posted by Michael Wonder on 01 Nov 2023
Cabozantinib maleate for previously treated adults with advanced differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine
1 November 2023 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) for previously treated adults with advanced differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine.
Cabozantinib maleate is not recommended for the treatment of adults with locally advanced or metastatic differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine, and that has progressed after systemic treatment
